# Ixabepilone Administered as an Enteric Coated Formulation.

> **NCT00309049** · PHASE1,PHASE2 · COMPLETED · sponsor: **R-Pharm** · enrollment: 30 (—)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Ixabepilone
- **DRUG:** Ixabepilone
- **DRUG:** Ixabepilone

## Key facts

- **NCT ID:** NCT00309049
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 30 (—)
- **Last updated:** 2017-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00309049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00309049, "Ixabepilone Administered as an Enteric Coated Formulation.". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00309049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*